BioSapien

BioSapien is a biotechnology company developing a localized drug delivery platform designed to improve the treatment of solid tumors. The company's core technology, MediChip, is a 3D-printed, biodegradable implant that provides sustained, high-dose delivery of chemotherapeutic agents directly to the tumor site while minimizing systemic toxicity. By focusing on local administration, BioSapien aims to transform standard-of-care treatments for difficult-to-treat cancers, starting with pancreatic cancer. The platform is designed to be compatible with various FDA-approved drugs, potentially extending the life cycle and efficacy of existing oncology therapeutics.